



ISLB
INTERNATIONAL SOCIETY
OF LIQUID BIOPSY



6TH ANNUAL CONGRESS

Liquid Biopsy

November 23-25, 2024 | Denver, Colorado, USA

PROGRAM BOOK



[2024.ISLB.INFO](https://2024.islb.info)



#ISLB24

**Explore resources
to learn more about
precision medicine
in oncology**

**and how to improve
patient access
to molecular testing
at your institution!**

Lilly

Available on
medical.lilly.com

**Explore
now**



Table of Contents

- 4 Welcome Message
- 5 Host Organization
- 6 Committee
- 7 Venue Floorplan
- 8 Program at a Glance
- 11 Full Congress Program
- 21 ISLB Award Lectures
- 22 Official Networking Events
- 23 Congress Partners
- 24 Exhibit & Poster Hall Information
- 25 Exhibitor Listing
- 30 General Congress Information
- 32 Save the Date for 2025
- 33 Poster Listing



Welcome Message

Welcome to the 6th Annual Congress of Liquid Biopsy: “Advancing and Accelerating Access of Liquid Biopsy” (ISLB 2024) in the captivating city of Denver, Colorado, USA.

Liquid biopsy stands at the forefront of medical innovation, poised to revolutionize cancer treatment and patient care. With exponential growth and transformative potential, our congress aims to propel the global adoption of liquid biopsies, dismantling barriers hindering their integration into routine clinical practice. Education, technological accessibility, standardization, and other critical factors are pivotal in shaping the future of this field.

Building upon the success of our previous in-person gathering in Madrid, Spain, which drew over 500 attendees, ISLB 2024 promises unparalleled excellence. Our chosen venue, the Convention Center, boasts state-of-the-art facilities and amenities, ensuring a seamless and enriching experience for all participants.

While Colorado’s natural splendor is renowned, Denver’s vibrant urban landscape offers a wealth of cultural and culinary delights. From museums and galleries to a thriving restaurant scene, Denver invites exploration and enjoyment. And with Thanksgiving just around the corner, nearby mountain retreats provide an enticing option for further adventure.

We are confident that our attendees will relish the dynamic atmosphere of Denver, departing with cherished memories and newfound knowledge from this unforgettable scientific exchange.

Mark your calendars and join us in Denver on November 23-25, 2024, as we collectively shape the future of liquid biopsy. Together, let us make ISLB 2024 an unparalleled scientific gathering, empowering liquid biopsy professionals for the challenges ahead.

We look forward to welcoming you all!

Christian Rolfo

ISLB President

On behalf of the ISLB Executive Committee



Host Organization

About ISLB

The International Society of Liquid Biopsies (ISLB), founded in 2017 in Granada, Spain, aims to bring together healthcare professionals, primarily oncologists and those who have adopted liquid biopsies as a cutting-edge clinical tool. We are pleased to welcome liquid biopsy professionals from around the world, and we strive to serve as a link among key stakeholders in this field.

By joining ISLB, members become part of an international community of healthcare professionals involved in the management of cancer patients, sharing best practices and the latest advancements in liquid biopsy use to ensure the successful implementation of this approach in cancer treatment and other diseases that may benefit from it. Membership benefits include free or discounted access to Critical Reviews in Oncology/Hematology publications, savings of up to \$100 on registration fees for the ISLB Annual Congress, free access to on-demand videos in the ISLB Virtual Library, eligibility to volunteer and join ISLB Committees, access to ISLB's annual awards and grants, and opportunities for networking with patient associations and international liquid biopsy consortiums.



Committee

Executive Committee



Christian Rolfo

ISLB President
United States



Maria Jose Serrano

ISLB Vice President
Spain



Umberto Malapelle

ISLB Scientific Secretary
Italy



Eloisa Jantus Lewintre

ISLB Treasurer
Spain



David Gandara

ISLB CMO
United States



Massimo Cristofanilli

ISLB Past President
United States



- Plenary Sessions
- Exhibits, Posters, Showcase Theatre
- Breakout Sessions, Advisory Board Meetings (Friday Only)
- Registration Desk and Membership Zone
- Advisory Board Meetings (Friday Only)


Venue Floorplan

Program at a Glance

Saturday, November 23, 2024

08:00	S01. Current Status of Circulating Tumor DNA in Selected Solid Tumors 08:00 - 09:30 Adams B	
08:30		
09:00		
09:30	S02. Navigating the Complex Landscape of Liquid Biopsy: Current Trends and Future Directions 09:30 - 11:00 Adams B	S03. Extracellular Vesicles and CTCs 09:30 - 11:00 Spruce 3-4
10:00		
10:30		
11:00	Morning Break Exhibit Hall Poster Session 11:00 - 12:30 Exhibit Hall (Adams C-D)	
11:30		
12:00		
12:30	Industry Symposium: Precision Cancer Consortium 12:45 - 13:45 Adams B 12:30 Lunch Box Pick Up	
13:00		
13:30		
14:00	Stakeholder Workshop 14:00 -15:30 Adams B	
14:30		
15:00		
15:30	Afternoon Break 15:30 - 15:45	
16:00	S04. Award Lectures 15:45 - 17:15 Adams B	
16:30		
17:00		
17:30	Opening Ceremony 17:15-18:15 Adams B	
18:00		
18:30		
19:00	Welcome Reception Posters Exhibits 18:15 - 20:30 Exhibit Hall (Adams C-D)	
19:30		
20:00		
20:30		

 Refreshments Provided

 Lunch Box Provided

ThermoFisher
SCIENTIFIC



Refreshments
Provided



Lunch Box
Provided

Welcome Reception
supported by

ThermoFisher
SCIENTIFIC

Program at a Glance

Sunday, November 24, 2024

08:00	Industry Symposium: Guardant Health 08:00 - 09:00 Adams B		 Continental Breakfast Provided
08:30			
09:00	S05. Liquid Biopsy for Early Cancer Detection 09:00 - 10:30 Adams B	S06. Next Generation Technologies in Liquid Biopsy 09:00 - 10:30 Spruce 3-4	
09:30			
10:00			
10:30	Morning Break Exhibit Hall Poster Session 10:30 - 12:00 Exhibit Hall (Adams C-D)		
11:00	Showcase Theatre: OncoHost 10:40 - 11:00 Exhibit Hall (Adams C-D)		 Refreshments Provided
11:30	Showcase Theatre: Qiagen 11:10 - 11:30 Exhibit Hall (Adams C-D)		
12:00			
12:30	Industry Symposium: Foundation Medicine 12:15 - 13:15 Adams B		 Lunch Box Provided
13:00	12:00 Lunch Box Pick Up		
13:30	Afternoon Break 13:15 - 13:30		
14:00	S07. Future Perspectives in Liquid Biopsy 13:30 - 15:00 Adams B	Workshop: ctDNA : Preanalytical and Post Analytical Standardization Workshop 13:30 - 15:00 Spruce 3-4	
14:30			
15:00			
15:30	S08. Keynote Session 15:10 - 16:30 Adams B		
16:00			
16:30			
17:00	Industry Symposium: Thermo Fisher Scientific 16:30 - 17:30 Adams B		
17:30			
18:00	Young Career Round Tables 17:30 - 19:00 Spruce 3-4		
18:30			
19:00			
19:30			
20:00			

Program at a Glance

Monday, November 25, 2024

08:00

Industry Symposium: OneCell Diagnostics

8:00 - 9:00 | Adams B



Continental
Breakfast
Provided

08:30

09:00

OA01. Preferred Abstracts

9:00 - 10:30 | Adams B

09:30

10:00

10:30

Morning Break | Exhibit Hall | Poster Session

10:30 - 11:30 | Exhibit Hall (Adams C-D)



Refreshments
Provided

11:00

11:30

12:00

S09. Accreditations and Minimal Requirements for Liquid Biopsy

11:30 - 13:00 | Adams B

12:30

13:00

Best Abstract Award & Closing Ceremony

13:00 - 14:00 | Adams B

13:30

14:00

Unlock the power of CTCs!



Meet us at Booth 111

The Parsortix® PC1 system is the first FDA cleared medical device for the capture and harvest of intact circulating tumour cells (CTCs) from metastatic breast cancer patient blood for subsequent user-validated analysis.

At its core is a unique method for capturing and harvesting intact CTCs and CTC clusters from whole blood for downstream analysis, which is non-invasive and can be repeated as often as needed.

At ANGLE we offer products for use in both clinical and research laboratories, as well as a bespoke biopharma testing service to support your clinical trial needs.

Meet our expert team to discover how CTCs can help enhance your work.

“Circulating tumour cells harvested by [the Parsortix PC1 system] are a good surrogate for tissue biopsies of the metastatic site”

Julie E. Lang

Chief of Breast Surgery, Cleveland Clinic

angleplc.com

MARK-109-AD-A

Full Congress Program

SATURDAY, NOVEMBER 23, 2024

08:00 – 09:30	S01. Current Status of Circulating Tumor DNA in Selected Solid Tumors Adams B
08:00 – 08:05	Chair David Gandara, ISLB - United States
08:05 – 08:20	S01.01 Role of the Pathologist in Liquid Biopsy for Therapeutic Decision Making Diana Ionescu, Bc Cancer, Ubc - Canada
08:20 – 08:35	S01.02 Update on Liquid Biopsy in Breast Cancer Massimo Cristofanilli, ISLB - United States
08:35 – 08:50	S01.03 Liquid Biopsy in Lung Cancer: Recent Applications of ctDNA in Early-Stage NSCLC David Gandara, ISLB - United States
08:50 – 09:05	S01.04 Current Status of Liquid Biopsy in Prostate Cancer Nicholas Mitsiades, University of California Davis Comprehensive Cancer Center - United States
09:30 – 11:00	S02. Navigating the Complex Landscape of Liquid Biopsy: Current Trends and Future Directions Adams B
09:30 – 09:35	Chairs Eloisa Jantus Lewintre, ISLB - Spain Christian Rolfo, ISLB - United States
09:35 – 09:50	S02.01 Liquid Biopsy in Radiation Oncology: Current Status Aadel Chaudhuri, Mayo Clinic - United States
09:50 – 10:05	S02.02 Single Cell Analysis and Clonal Hematopoiesis. Implications in Liquid Biopsy for Solid Tumors. Franco Izzo, Icahn School Of Medicine At Mount Sinai - United States
10:05 – 10:30	S02.03 Rationale for Concurrent Tissue + Plasma ctDNA analysis at Cancer Diagnosis Natasha Leighl, Princess Margaret Cancer Centre - Canada
10:20 – 10:35	S02.04 Tumor Fraction Calculation in cfDNA Christian Rolfo, ISLB - United States
10:35 – 11:00	Panel Discussion Umberto Malapelle, ISLB - Italy Valsamo Anagonostou, Johns Hopkins School of Medicine - United States

09:30 – 11:00 S03. Extracellular Vesicles and CTCs

Spruce 3-4

09:30 – 09:35 Chairs

Maria Jose Serrano, ISLB - Spain

Nicola Fusco, European Institute of Oncology - Italy

09:35 – 09:50 S03.01 Applicability of CTC Screening in Daily Clinical Practice

Paul Hofman, IHU RespirERA - France

09:50 – 10:05 S03.02 CTC in Breast Cancer

Carolina Reduzzi, Weill Cornell Medicine - United States

10:05 – 10:20 S03.03 Lipidomic Profiling of Extracellular Vesicles

Julia Burnier, McGill University - Canada

10:20 – 10:35 S03.04 Extracellular Vesicles as Potential Biomarkers for Diagnosis and Recurrence Detection of Hepatocellular Carcinoma

Augusto Villanueva, Icahn School of Medicine at Mount Sinai - United States

10:35 – 11:00 Panel Discussion

Massimo Cristofanilli, ISLB - United States

Anthony Lucci, MD Anderson Cancer Center - United States

11:00 – 12:30 Morning Break

Exhibits/ Posters I Exhibit Hall (Adams C-D)

**REFRESHMENTS
PROVIDED****12:30 – 12:45 Bio Break**

Outside Adams B

Pick up your Lunch Box Sponsored by Precision Cancer Consortium

12:45 – 13:45 Industry Symposium: Precision Cancer Consortium | Adams B**LUNCH BOX
PROVIDED****Expanding Access and Adoption of Liquid Biopsy in Routine Clinical Care: *Expert Insights, Practical Solutions, and Your Chance to Join the Conversation***

The Precision Cancer Consortium (PCC), believes that liquid biopsy plays a crucial role in expanding global access to comprehensive genomic profiling and improving patient outcomes. Join the PCC at their sponsored symposium, where Dr Simon Heeke will explore the contrast between utilization of comprehensive genomic profiling in academic settings with its use in community practice, and how liquid biopsy (LBx) can play a role in bridging this gap to improve patient access. Drs Paul Hofman and Bruna Pellini will then participate in a 'fireside chat', discussing the landscape, challenges, and real-world solutions surrounding LBx access and adoption.

The Precision Cancer Consortium (PCC) is a non-profit organization dedicated to driving global access to comprehensive genomic testing for all patients with cancer. The PCC is composed of and funded by: AstraZeneca, Bayer, GSK, Johnson & Johnson, Lilly, Novartis, and Roche, at time of writing

PCC-108 | Date of prep: October 2024

14:00 – 15:30 Stakeholder Workshop

Adams B

14:00 – 14:05 Chair

David Gandara, ISLB - United States

14:05 – 14:45 Panel 1: Clinical Application of Liquid Biopsy: Greatest Challenges and Opportunities

Hashem Alshurafa, Guardant Health - United States

Mary Redman, Fred Hutchinson Cancer Research Center - United States

Paz Vellanki, FDA - United States

Ola Khorshid, Nci Cairo University – Egypt

Daniel Hicks, IASLC - United States

David Kozono, Dana-Farber Brigham Cancer Center - United States

Jean-Francois Pouliot, Regeneron - United States

Ofer Sharon, OncoHost - Israel

Biljana Naumovic, Johnson & Johnson - United States

14:45 – 14:50 Chair

Christian Rolfo, ISLB - United States

14:50 – 15:30 Panel 2: Technology- Translational

Abhijit Patel, Yale University - United States

Paz Vellanki, FDA - United States

Murry Wynes, Go2 for Lung Cancer - United States

David Kozono, Dana-Farber Brigham Cancer Center - United States

Luca Quagliata, Thermo Fisher Scientific - Italy

Adam Sowalsky, National Cancer Institute - United States

15:30 – 15:45 Bio Break**15:45 – 17:15 S04. Award Lectures**

Adams B

15:45 – 15:50 Chairs

Maria Jose Serrano, ISLB - Spain

Christian Rolfo, ISLB - United States

15:50 – 16:15 S04.01 Application of Circulating Tumor DNA Analyses to Unmet Clinical Needs

Luis Diaz, Memorial Sloan Kettering - United States

16:15 – 16:40 S04.02 ctDNA – From Proof-of-Principle to Clinical Implementation

Ellen Heitzer, Medical University of Graz - Austria

16:40 – 5:05 S04.03 Frontiers in Cell-free DNA Fragmentomics

Dennis Lo, The Chinese University Of Hong Kong - Hong Kong

17:15 – 18:15 Opening Ceremony

Adams B

17:15 – 17:20 ISLB activities during 2023

Christian Rolfo, ISLB - United States

Maria Jose Serrano, ISLB - Spain

17:20 – 17:25 Course of Advanced Study

David Gandara, ISLB - United States

17:25 – 17:30 Update on the Journal of Liquid Biopsy and CROH

Umberto Malapelle, ISLB - Italy

17:30 – 17:35 Relationship with the Other Societies

Eloisa Jantus Lewintre, ISLB – Spain

17:35 – 17:40 Presentation of the Communication Committee

Yüksel Ürün, Ankara University School of Medicine; Department of Medical Oncology - Turkey

17:40 – 17:45 Presentation of the Educational Committee

Natasha Leighl, Princess Margaret Cancer Centre - Canada

17:45 – 17:50 Presentation of the Young Committee

Carolina Reduzzi, Weill Cornell Medicine - United States

17:50 – 17:55 Presentation of the Quality and Accreditation Committee

Nicola Fusco, European Institute of Oncology - Italy

17:55 – 18:00 Presentation of the Publications Committee

Charu Aggarwal, University of Pennsylvania - United States

18:00 – 18:05 Presentation of the Membership Committee

Bruna Pellini, Moffitt Cancer Center - United States

18:05 – 18:10 Presentation of the Committee on Developing Countries

Ola Khorshid, Nci Cairo University - Egypt

18:10 – 18:15 Final Remarks

Massimo Cristofanilli, ISLB - United States

18:15 – 20:30 Welcome Reception - Supported by Thermo Fisher Scientific Exhibits/Posters

Exhibit Hall (Adams C-D)

SUNDAY, NOVEMBER 24, 2024

08:00 – 09:00 Industry Symposium: Guardant Health

Adams B



Infinite Possibilities: Expanding Utility and Enabling Analysis of Liquid Biopsy in Precision Oncology

This symposium will highlight the innovation in liquid biopsy through epigenomics across the continuum of cancer care. We will highlight the nuances of epigenomics in carcinogenesis and its ability to extend utility of liquid biopsy beyond genomics-based technologies, particularly that of the Guardant Infinity platform. Additionally, we will highlight data – both generated at Guardant and outside of Guardant – that reviews the development of signatures and applications of epigenomics to further refine precision medicine. We will then highlight the current and future capabilities of multi-modal datasets to harness to continue biomarker discovery and outcomes-based research, highlighting the clinico-genomics database, Guardant INFORM.

09:00 – 10:30 S05. Liquid Biopsy for Early Cancer Detection

Adams B

09:00 – 09:05 Chairs

Christian Rolfo, ISLB - United States

Valsamo Anagnostou, Johns Hopkins School of Medicine - United States

09:05 – 09:20 S05.01 Early Detection of Renal Cell Carcinoma

Jacob Berchuck, Winship Cancer Institute of Emory University - United States

09:20 – 09:35 S05.02 Early Cancer Detection in Li-Fraumeni Syndrome with Cell-Free DNA.

Trevor Pugh, Princess Margaret Cancer Centre, Ontario Institute for Cancer Research - Canada

09:35 – 09:50 S05.03 Early Detection in Lung Cancer

Christian Rolfo, ISLB - United States

09:50 – 10:05 S05.04 miRNAs in Blood and Urine as Companion Diagnostic Biomarkers in Genitourinary Tumours

Marta Dueñas, Fundación de Investigación Biomédica Hospital 12 de Octubre - Spain

09:00 – 10:30 S06. Next Generation Technologies in Liquid Biopsy

Spruce 3-4

09:00 – 09:05 Chairs

Eloisa Jantus Lewintre, ISLB - Spain

Maria Jose Serrano, ISLB - Spain

09:05 – 09:20 S06.01 Next Generation Trial Design in Liquid Biopsy

Mary Redman, Fred Hutchinson Cancer Research Center - United States

09:20 – 09:35 S06.02 The future of Bioinformatics in Liquid Biopsy Research
Giovanni Nigita, The Ohio State University Comprehensive Cancer Center - United States

09:35 – 09:50 S06.03 ctDNA Methylation Analysis for Early Detection
Abhijit Patel, Yale University - United States

09:50 – 10:05 S06.04 Multidimensional ctDNA Testing
Umberto Malapelle, ISLB - Italy

10:05 – 10:30 Panel Discussion
Paul Hofman, IHU RespirERA - France
Simon Patton, EMQN CIC - United Kingdom

**10:30 – 12:00 Morning Break
Showcase Theatre/ Exhibits/ Posters**
Exhibit Hall (Adams C-D)
Showcase Schedule OncoHost: 10:40 – 11:00
Qiagen: 11:10 – 11:30



**REFRESHMENTS
PROVIDED**

10:40 – 11:00 Showcase Theatre: OncoHost
Exhibit Hall (Adams C-D)

Cutting-Edge Biomarkers: How Proteomics and AI are Shaping the Future of Immunotherapy

Given the intricate relationship between therapy, tumor, and host, biomarker development for immunotherapy requires a holistic, system-wide approach. Multicomponent biomarkers in the blood offer significant potential by providing a more complete view of the underlying biological signals.

Dr. Harel will discuss the challenges in developing biomarkers for immunotherapy and how these are being addressed through the PROphet platform. By harnessing plasma proteomics and machine learning algorithms, this platform enables the prediction of treatment efficacy and toxicity, offering a valuable tool for informing treatment decisions in non-small cell lung cancer and other indications.

Attendees will gain insights into how this innovative tool provides comprehensive clinical assessments, empowering physicians to make more informed, personalized treatment decisions with a single blood test.

11:10 – 11:30 Showcase Theatre: Qiagen
Exhibit Hall (Adams C-D)

Evaluation of Preanalytical Workflows for Molecular Profiling of Urinary Cell-Free DNA in Malignant Diseases

Ellen Heitzer, Medical University Graz - Austria

12:00 – 12:15 Bio Break
Outside Adams B
Pick up your Lunch Box Sponsored by Foundation Medicine



ctDNA Revolution: Shaping the Future of Cancer Care with Next Generation Biomarkers and Real-Time Treatment Monitoring

Foundation Medicine's symposium will explore the transformative role of circulating tumor DNA (ctDNA) in modern cancer care. As precision medicine advances, non-invasive ctDNA technologies are revolutionizing treatment selection and treatment response monitoring, offering real-time insights into treatment efficacy and even tumor evolution. This presentation will highlight cutting-edge developments, such as the use of ctDNA in monitoring applications, and how ctDNA can be used in adaptive trial design. You'll also learn how next-generation algorithms such as ctDNA tumor fraction and CH along with advanced genomic sequencing are enabling clinicians to gather deeper insights to tumor biology.

13:15 – 13:30 Bio Break

13:30 – 15:00 S07. Future Perspectives in Liquid Biopsy

Adams B

13:30 – 13:35 Chairs

Christian Rolfo, ISLB - United States

Natasha Leighl, Princess Margaret Cancer Centre - Canada

13:35 – 13:50 S07.01 Immune-related Predictive Biomarkers in NSCLC

Valsamo Anagonostou, Johns Hopkins School of Medicine - United States

13:50 – 14:05 S07.02 HPV Circulating Tumor DNA

Lillian Siu, Princess Margaret Cancer Centre - Canada

14:05 – 14:20 S07.03 ctDNA for Monitoring Immunotherapy

Erin Schenk, University of Colorado - United States

14:20 – 14:35 S07.04 Liquid Biopsy in GI Cancer

Sameek Roychowdhury, The Ohio State University - United States

14:35 – 15:00 Panel Discussion

Maria Jose Serrano, ISLB - Spain

David Gandara, ISLB - United States

13:30 – 15:00 Workshop: ctDNA : Preanalytical and Post Analytical Standardization Workshop

Spruce 3-4

13:30 – 13:35 Chairs

Nicola Fusco, European Institute of Oncology - Italy

Eloisa Jantus Lewintre, ISLB - Spain

13:35 – 13:55 Lessons Learned from Quality Control Assessment Program on Liquid Biopsy

Simon Patton, EMQN CIC - United Kingdom

13:55 – 14:55 Workshop Panel

Silvia Calabuig Fariñas, University of Valencia - Spain

Paul Hofman, IHU RespirERA - France

Ellen Heitzer, Medical University of Graz - Austria

Jose Luis Costa, Thermo Fisher Scientific - Portugal

Simon Heeke, UT MD Anderson Cancer Center - United States

14:45 – 15:00 Panel Discussion**15:00 – 15:10 Bio Break****15:10 – 16:30 S08. Keynote Session**

Adams B

15:10 – 15:15 Chair

Christian Rolfo, ISLB - United States

15:15 – 15:35 S08.01 Cell-free DNA Screening for Nasopharyngeal Carcinoma

Dennis Lo, The Chinese University Of Hong Kong - Hong Kong

15:35 – 15:55 S08.02 Blood Based Test for Colorectal Cancer Screening

Daniel Chung, Massachusetts General Hospital - United States

15:55 – 16:15 S08.03 Early Detection of Molecular Residual Disease limitations and Opportunities

Aadel Chaudhuri, Mayo Clinic - United States

16:30 – 17:30 Industry Symposium: Thermo Fisher Scientific

Adams B

Liquid Biopsy, Quo Vadis? Real-World Clinical Case Examples in 2024 and Future Applications in Oncology

This symposium is set to offer an engaging and informative session for clinicians, researchers, and industry professionals. By featuring real-world cases and fostering dynamic discussions, it will serve as a platform for exchanging valuable knowledge and driving forward the conversation on the future of liquid biopsy in oncology.

Each panelist will present their unique cases, showcasing how liquid biopsy has been effectively used in their respective clinical practices. The format is designed to promote interaction not only between the panelists but also with the audience. The emphasis will be on creating a lively dialogue, where panelists will share their insights, discuss challenges, and compare perspectives on how liquid biopsy is shaping the future of oncology.

This interactive format promises to create a rich learning environment, making this a must-attend event for those interested in the cutting-edge applications of liquid biopsy.

17:30 – 19:00 Young Career Round Tables

Spruce 3-4

17:30 – 17:40 Chairs

Konstantinos Venetis, IEO, European Institute of Oncology - Italy

Eleonora Nicolò, Weill Cornell Medicine - United States

Carolina Reduzzi, Weill Cornell Medicine - United States

17:40 – 19:00 Roundtable Panel

Simon Heeke, UT MD Anderson Cancer Center - United States

Julia Burnier, McGill University - Canada

Luca Quagliata, Thermo Fisher Scientific - Italy

Bruna Pellini, Moffitt Cancer Center - United States

MONDAY, NOVEMBER 25, 2024**08:00 – 09:00 Industry Symposium: OneCell Diagnostics**

Adams B

**Chartering the Future of Liquid Biopsy: ctDNA + CTC Multi-omics (DNA+RNA+Proteins)**

Leading liquid biopsy experts Dr David Gandara and Dr Christian Rolfo and other panelists will discuss the landscape of blood-based biomarkers for therapy response and resistance. They will focus on platforms for blood-based RNA and Proteomics, including CTCs, highlighting the latest scientific evidence from ASCO and AACR supporting the utility of these platforms.

Why is this important?

ctDNA based liquid biopsy panels have been adequate for targeted therapy and immunotherapy response and resistance monitoring. However, with the approval of new therapies, including ADC (antibody drug conjugates) and Bi-specifics, it has become important to integrate highly sensitive, multiplexed blood-based RNA/transcriptomics and Proteomics to detect markers of response and resistance.

09:00 – 10:30 OA01. Preferred Abstracts

Adams B

09:00 – 09:05 Chairs

Carolina Reduzzi, Weill Cornell Medicine - United States

Diego De Miguel Perez, The Ohio State University - United States

09:05 – 09:10 OA01.01 Predicting Genitourinary Cancer Tissue-of-origin Using Urine Cell-free DNA Fragmentomic Features

Pradeep Chauhan, Mayo Clinic - United States

09:10 – 09:25 OA01.02 Circulating T-cell Receptor Repertoire Analysis Improves Cancer Early Detection

Roman Yelensky, Serum Detect, Inc. - United States

09:25 – 09:30	OA01.03 Cerebrospinal Fluid Circulating Tumour DNA Profiling for Risk Stratification and Matched Treatment for Central Nervous System Metastases of NSCLC metastases of NSCLC Meimei Zheng, Guangdong Provincial People's Hospital - China	
09:30 – 09:45	OA01.04 Discovering New Markers to Optimize the Detection of Circulating Tumor Cells Sina Naserian, ScreenCell - France	
09:45 – 09:50	OA01.05 Real-World Experience of the Decentralized MSK-ACCESS powered with SOPHiA DDM Solution Florian Klemm, SOPHiA Genetics - Switzerland	
09:50 – 09:55	OA01.06 Expanding clinical impact of liquid biopsy beyond genomics: exploration of novel epigenomic applications Leslie Bucheit, Guardant Health - United States	
10:30 – 11:30	Morning Break Exhibits/Posters Exhibit Hall (Adams C-D)	 REFRESHMENTS PROVIDED
11:30 – 13:00	S09. Accreditations and Minimal Requirements for Liquid Biopsy Adams B	
11:30 – 11:35	Chairs Umberto Malapelle, ISLB - Italy Nicola Fusco, European Institute of Oncology - Italy	
11:35 – 11:50	S09.01 Liquid Biopsy Laboratory Accreditation Process Silvia Calabuig Fariñas, University of Valencia - Spain	
11:50 – 12:05	S09.02 The Policy for Accreditation Process Denis Horgan, European Alliance For Personalised Medicine - Belgium	
12:05 – 12:20	S09.03 Minimal Requirements for ctDNA Testing on Liquid Biopsy in Solid Tumors: ISLB Quality Control & Accreditations Committee Working Group Konstantinos Venetis, IEO, European Institute of Oncology - Italy	
12:20 – 12:35	S09.04 Minimal Requirements in Bioinformatic for Accreditation Giovanni Nigita, The Ohio State University Comprehensive Cancer Center - United States	
12:35 – 13:00	Panel Discussion Aadel Chaudhuri, Mayo Clinic - United States Maria Jose Serrano, ISLB - Spain	
13:30 – 14:00	Best Abstract Award & Closing Ceremony Adams B	

ISLB Awards Lectures



Dr. Luis Diaz

S04.01 Application of Circulating Tumor DNA Analyses to Unmet Clinical Needs

ISLB Lifetime Achievement Award

Dr. Diaz is a pioneer in cancer genomics. His teams were the first to track circulating tumor DNA for the early detection of cancer, tracking resistance and for the detection of minimal residual disease; and discover the therapeutic link between cancer genetics and immunotherapy in mismatch repair deficient tumors.



Prof. Ellen Heitzer

S04.02 ctDNA – From Proof-of-Principle to Clinical Implementation

ISLB Research Award

Ellen Heitzer is a Clinical Laboratory Geneticist at the Institute of Human Genetics in Graz, AUSTRIA. She is heading the Research Unit for “Liquid Biopsies for personalized medicine in cancer”.



Prof. Dennis Lo

S04.03 Frontiers in Cell-free DNA Fragmentomics

ISLB Innovation in Liquid Biopsy Award

Professor Lo discovered the presence of cell-free fetal DNA in maternal blood in 1997. He has spearheaded the development of non-invasive prenatal testing (NIPT) which is now used worldwide. He has also pioneered technologies for the detection of cancer using peripheral blood.



Welcome Reception

We invite all delegates to join us for the Welcome Reception marking the beginning of an exciting few days filled with dynamic presentations, insightful posters, and a comprehensive exhibition. This event offers an opportunity for attendees to connect and network with peers and colleagues.

Supported by

ThermoFisher
SCIENTIFIC

Date: Saturday, November 23, 2024

Time: 18:15 - 20:30

Location: Exhibit Hall, Adams C-D

Congress Badge is required for entry**

Congress Partners

ISLB 2024 would like to thank our generous Partners & Supporters.

GOLD



SILVER



BRONZE



SUPPORTERS



Exhibit & Poster Hall Information

Exhibit Hall and Poster Hours

Saturday, November 23	10:30 - 16:00 18:15 - 20:30
Sunday, November 24	10:00 - 15:00
Monday, November 25	10:00 - 12:00

Welcome Reception Supported by

ThermoFisher
SCIENTIFIC

Saturday, November 23 18:15 - 20:30

Showcase Theatre

Sunday, November 24 10:40 - 11:00

 **ONCOHOST**
GUIDED ONCOLOGY


Sunday, November 24 11:10 - 11:30


QIAGEN

Exhibit Hall Floorplan

Exhibitors

ANGLE	111
Biofidelity	310
Bio-Rad Laboratories	210
Caris Life Sciences	105
DNA Genotek	304
Foundation Medicine	302
GT Molecular	211
J&J Innovative Medicine	103
Menarini Silicon Biosystems	309
OncoHost	203
OneCell Diagnostics	303
Pfizer Oncology	109
QIAGEN	209
Tecan	311
Tempus	204
Tethis S.p.A.	305
Thermo Fisher Scientific	205



Exhibitor Listing



ANGLE | Booth #111

ANGLE is a world-leading liquid biopsy company based in the UK, its patented Parsortix® PC1 system is the first FDA cleared device for the capture and harvest of intact circulating tumour cells (CTCs) from metastatic breast cancer patient blood.

angleplc.com



Biofidelity | Booth #310

Biofidelity is a rapidly growing commercial-stage genomic technology company dedicated to improving and extending the lives of patients with cancer by enabling better targeting of therapies, early detection of treatment resistance and routine monitoring of treatment response. Visit biofidelity.com and connect with us on LinkedIn and X.

biofidelity.com



Bio-Rad Laboratories | Booth #210

Bio-Rad is a global leader of innovative products for life sciences and clinical diagnostics. Our technologies focus on bioprocessing, protein characterization, and cell and 'omics analyses to advance scientific discovery and improve healthcare. Our customers include universities, research facilities, hospitals, public health and commercial labs, biopharma, and applied laboratories.

bio-rad.com



Caris Life Sciences | Booth #105

Caris Life Sciences® is the leading molecular science and technology company developing and delivering innovative solutions to revolutionize healthcare and improve patient outcomes. Caris' suite of market-leading molecular profiling offerings assesses DNA, RNA and proteins, revealing a molecular blueprint helping physicians better detect, diagnose and treat patients.

carislifesciences.com



DNA Genotek | Booth #304

DNA Genotek Inc. distributes Colli-Pee™ devices for self-collected, volumetric first-void urine sampling, enhancing the quality of diagnostic tests for infectious diseases and oncology. Backed by strong clinical research outcomes and patient preference, the Colli-pee device standardizes collection, and enables the immediate mixing of urine with preservative for sample stability.

dnagenotek.com



Foundation Medicine | Booth #302

Foundation Medicine is a pioneer in molecular profiling for cancer, working to shape the future of clinical care and research. We collaborate with a broad range of partners across the cancer community and strive to set the standard for quality, scientific excellence, and regulatory leadership. Our deep understanding of cancer biology helps physicians make informed treatment decisions for their patients and empowers researchers to develop new medicines. We are driven to help our partners find answers and take action as we work to transform cancer care.

foundationmedicine.com



GT Molecular | Booth #211

GT Molecular provides ultrasensitive digital and Real-Time PCR assays for pathogen quantification and advancing cancer research. Our multiplex oncology (RUO) assay kits are optimized and validated using real patient samples, providing high-performance, easy-to-use results with primers, probes, and controls included. Sample logistics management, PCR and NGS testing services also available.

gtmolecular.com

Johnson & Johnson

J&J Innovative Medicine I Booth #103

Patients inform and inspire our science-based innovations, which continue to change and save lives. Applying rigorous science and compassion, we confidently address some of the most complex diseases of our time and unlock the potential medicines of tomorrow. Our diverse portfolio spans multiple therapeutic areas — Oncology, Immunology, Neuroscience, Cardiovascular, Pulmonary Hypertension, and Retina. We are continuously working to develop treatments, aspiring to find cures, pioneering the path from lab to life, and championing patients every step of the way.

janssen.com



Menarini Silicon Biosystems I Booth #309

Menarini Silicon Biosystems' CLIA lab uses CELLSEARCH® to offer a minimally invasive approach to follow a cancer patient's therapeutic journey by providing a standardized and reliable count of circulating tumor cells. MenariniSearch comprehensive genomic profiles identify a broader range of genetic alterations, empowering you to discover novel biomarkers and therapeutic targets.

siliconbiosystems.com



OncoHost I Booth #203

OncoHost is a technology company transforming the approach to precision medicine for improved patient outcomes. Its PROphet® platform is a plasma-based proteomic pattern analysis tool whose NSCLC test guides first-line immunotherapy decisions. OncoHost is led by an experienced team of entrepreneurs and industry experts, supported by a large-scale clinical trial.

oncohost.com



OneCell Diagnostics | Booth #303

OneCell Diagnostics Inc. is a Cupertino, USA-based precision oncology company specializing in liquid biopsy, single-cell multiomics, and digital pathology innovations. Incorporated in India, the company operates its Research and Diagnostic labs in California, USA, and Pune, India. OneCell Diagnostics is on a mission to democratize precision cancer monitoring and surveillance for early detection of cancer recurrence. By leveraging genomics data and Artificial Intelligence (AI), OneCell Diagnostics aims to impact millions of cancer patients worldwide, offering high-quality precision therapy options to those in need.

onecelldx.com



Pfizer Oncology | Booth #109

At Pfizer Oncology, we are at the forefront of a new era in cancer care. Our industry-leading portfolio and extensive pipeline includes three core mechanisms of action to attack cancer from multiple angles, including small molecules, antibody-drug conjugates (ADCs), and bispecific antibodies, including other immune-oncology biologics. We are focused on delivering transformative therapies in some of the world's most common cancers, including breast cancer, genitourinary cancer, hematology-oncology, and thoracic cancers, which includes lung cancer. Driven by science, we are committed to accelerating breakthroughs to help people with cancer live better and longer lives.

pfizer.com



QIAGEN | Booth #209

QIAGEN serves more than 500,000 customers globally, all seeking insights from DNA, RNA and proteins. Using any biological sample, they are advancing science and improving outcomes for people everywhere. Our products for molecular testing serve applications from basic life sciences research to clinical healthcare. Together, we are making improvements in life possible.

qiagen.com



Tecan | Booth #311

Tecan's purpose is to improve people's lives and health by empowering customers to scale healthcare innovation globally, from life science to the clinic. We collaborate with our customers in healthcare and the life sciences, from early-stage innovation through project implementation and beyond. We deliver the products, services and solutions that make lab processes and medical procedures precise, reproducible and compliant. Together, we are shaping a brighter, healthier future, for patients across the world.

tecان.com



Tempus | Booth #204

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data.

tempus.com



Tethis S.p.A. | Booth #305

Tethis S.p.A., an Italian diagnostic company, is introducing the first automated platform that standardizes plasma and cytology sample preparations for multiomics liquid biopsy.

tethis-lab.com



Thermo Fisher Scientific | Booth #205

Thermo Fisher Scientific Inc. is the world leader in serving science. Our Mission is to enable our customers to make the world healthier, cleaner and safer. We are committed to enabling advancements in precision oncology through our Ion Torrent brand of next-generation sequencing (NGS) instrumentation and Oncomine portfolio of assays, democratizing access to molecular profiling through fast, automated, and reliable solutions.

oncomine.com



PUSH THE BOUNDS OF SCIENCE

MAKE LIFE-CHANGING MEDICINES

Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories.

Learn more at www.regeneron.com/global

REGENERON[®]

Copyright © 2024 Regeneron Pharmaceuticals, Inc. All rights reserved. US-UNB-EM-24-07-0002 September 2024

General Congress Information



Venue

Gaylord Rockies Convention Center
6700 N Gaylord Rockies Blvd., Aurora,
CO 80019



Access / Security

Name badges will be provided to all attendees, sponsors, and exhibitors and will be available for pick up at the Registration Desk (see venue map). Please wear your badge at all times as it is your admission to all Congress sessions, Exhibit & Poster Hall, and non-ticketed social events. Any lost badges will incur a 50 EUR reprint fee.



Language

The official language of ISLB 2024 is English. All sessions will be conducted in English.



Parking

Self-Parking: \$33 plus tax
Valet: \$48 plus tax per night.

Tell your check-in agent you have a vehicle on the property for unlimited access in and out of the resort gates (self-park \$33.00, valet \$48.00 plus tax per night). You are welcome to unload your vehicle on the front drive; however, cars are not permitted to be left unattended.



Lost Property

Please report any lost or unattended items immediately to the ISLB 2024 Registration Desk. Should you lose anything while at Congress, please enquire at the Registration Desk where any recovered lost property will be held. At the end of the congress, all unclaimed lost and found items will be given to Gaylord Rockies Convention Center.



Morning Breaks

Refreshments provided

Location: Exhibit Hall (Adams C-D)

November 23: 11:00 – 12:30

November 24: 10:30 – 12:00

November 25: 10:30 – 11:30



Registration Hours

Location: Adams B Foyer

November 22: 15:00 – 20:00

November 23: 07:00 – 20:00

November 24: 07:00 – 19:00

November 25: 07:00 – 12:00



Wi-Fi

Wi-Fi is complimentary if staying at the resort.



6TH ANNUAL CONGRESS
Liquid Biopsy
November 23-25, 2024 | Denver, Colorado, USA

Mobile App



Google Play



App Store

Alternatively, please search for the “The Event App by EventsAIR” in your respective App Store.

Once downloaded, enter the following

Event Code **islb2024**

Login using the email address and PIN sent to you in your final confirmation email. Please do not share the PIN number; it is your unique PIN connected to your registration record.



See You at
ISLB 2025
in Orlando, USA!

November 1-3,
2025

GET SOCIAL!



#ISLB25



ISLB
INTERNATIONAL SOCIETY
OF LIQUID BIOPSY

2025.islb.info



Poster Listing

Advocacy & Regulatory Aspects of Liquid Biopsy

PP01.01

Developing Novel Primary Reference Materials to Support Standardisation in Liquid Biopsy.

Leandro Lo Cascio, United Kingdom

PP01.02

External Quality Assurance for Circulating Free (cfDNA) Testing in Prostate Cancer: Observations and Future Perspectives.

Arfa Maqsood, United Kingdom

Clinical Applications of Liquid Biopsy

PP01.04

Methylation Based ctDNA Serial Monitoring Correlates with Immunotherapy Response in Non-Small Cell Lung Cancer

Angela Hsiao, United States

PP01.06

Novel Technology Affords Real-Time PCR the Sensitivity Required for Minimal Residual Disease Monitoring

Mary Stischer, United States

PP01.05

Characterization of Plasma Cell Free DNA Variants as Tumor-derived vs. Clonal Hematopoiesis of Indeterminate Potential (CHIP) in 11,457 Cancer Patients

Daniel Magee, United States

PP01.07

Real World Circulating Tumor DNA Detection in Advanced Pan-cancers by Timing of Liquid Biopsy Relative to Therapy

Vivek Subbiah, United States

Clinical Applications of Liquid Biopsy

PP01.08

Liquid Biopsy for Monitoring Response in KRAS-Mutated NSCLC Patients Treated with First-Line Immunotherapy

Ester Munera-Maravilla, Spain

PP01.09

Association of Circulating Tumor DNA Genotyping and Computed Tomography Radiomics with Clinical Outcomes in Patients with Advanced NSCLC

Alberto Ranghiero, Italy

PP01.10

NSCLC Exosomes: Unlocking Biomarker Potential

Susana Torres-Martínez, Spain

Clinical Applications of Liquid Biopsy

PP01.11

Detection of ctDNA After Neoadjuvant Chemotherapy Predicts Distant Relapse-Free Survival, Local and Distant Recurrence in TNBC: Findings from TRICIA Study

Talia Roseshter, Canada

PP01.12

High-sensitivity Detection and Broad Genomic Profiling in HR+/HER2- Breast Cancer: Final Comparative Results Using Targeted Single-gene and Broad-panel Sequencing Assays

Marija Balic, United States

PP01.13

Optimization and Evaluation of a Novel CTC Culture Protocol Using 'Reset' Vascular Endothelial Cells (R-VECs) and Microfluidic Enrichment.

Nadia Bayou, United States

PP01.14

Clinical Utility of Body Fluids for Multiplexed Detection of Genetic Alterations in Cancer Patients.

Beatriz Beatriz Garciam, España

PP01.15

Determination of Tumor PSMA Expression and Lutetium-PSMA Response in Men With Prostate Cancer Using a Novel Epigenomic Liquid Biopsy Platform

Praful Ravi, United States

PP01.16

Circulating Tumor DNA as Part of the Routine Work-up for Patients with Suspected Advanced Lung Cancer

Tia Brasoveanu, Canada

PP01.17

A First-Line Approach: Liquid Biopsy-Guided Osimertinib Therapy for EGFR-Mutated NSCLC

Silvia Calabuig-Fariñas, Spain

PP01.18

Next Gen Liquid Biopsy: Comprehensive Analysis from a Single Tube of Blood

Jon Ladd, United States

PP01.19

Expert Opinion Recommendations for External Quality Assessment for Liquid Biopsy Testing from the European Liquid Biopsy Society ctDNA Workshop

Zandra Deans, United Kingdom

PP01.21

Transforming the Lung Cancer Diagnostic Pathway with Liquid Biopsy: Early Genomic Results from the QuicDNA Biomarker Study in Wales

Rachel Dodds, United Kingdom

PP01.22

Characterizing cell-free DNA from healthy BRCA2-999del5 carriers

Berglind Ósk Einarsdóttir, Iceland

PP01.23

ASPYRE-Lung Blood: Validation Of A Simple, Fast and Robust Method For Molecular Profiling Of Actionable Variants In Plasma

Ryan Evans, United States

PP01.24

Monitoring GALNT13 in Blood of NSCLC Patients With Serial Evaluation Using Digital RT-PCR. A potential New Liquid Biopsy Biomarker

Eugenia Fernández Armúa, Uruguay

PP01.25

Impact on the Therapeutic Decision of Massive Gene Sequencing (NGS) in Plasma From Patients With Advanced Cancer.

Leonor Fernández-Murga, España

PP01.26

An mDETECT Assay for Monitoring Treatment Response in Metastatic Breast Cancer Patients

Keira Frosst, Canada

PP01.27

Liquid biopsy in Real-life: Experience of a Cancer Center Collecting Samples From Multiple Institutions in an Italian Regional Cancer Network

Gianluca Sacco, Italia

PP01.28

Expanding the Impact of Liquid Biopsies in Patients with Newly Diagnosed Advanced Lung Cancer (ExpandingLUNG)

Adrian G. Sacher, Canada

PP01.29

BRAF V600 Mutations Detection in Melanoma: A Cross-Methodological Study Using cfDNA

Eloisa Jantus Lewintre, España

PP01.30

Expression of Programmed Death - Ligand 1 as a Dynamic Biomarker on Circulating Tumor Cells in Pancreatic Cancer Patients

Jayant Khandare, India

PP01.31

Transit of Circulating Tumor Cells (Ctc) Post Radiotherapy at Irradiated Tumor Regions in Pan-Cancer Patients

Jayant Khandare, India

PP01.32

Comprehensive Analysis of ctDNA and CTCs Reveals Resistance Signatures and Correlations with PET Scan Outcomes in Cancer Patients

Gowhar Shafi, India

PP01.33

Downstream Effector Mutations Indicate Potential Tyrosine Kinase Inhibitor Resistance in EGFR Mutated Lung Cancer Patients

Gowhar Shafi, India

PP01.34

Evaluation of a New Vacuum Blood Collection Tube for Cell-Free DNA

□ Kuniya Komai, Japan

PP01.35

DISCOVER: Plasma Testing in Patients With Advanced Undergenotyped NSCLC and in Targeted Therapy Resistance.

Abdulrahman Alghabban, Canada

PP01.37

Multimodal Urine-based Accurate and Non-invasive Tool for Predicting Immunotherapy Response in Bladder Cancer

Álvaro Martín de Bernardo, Spain

PP01.38

Genomic-epigenomic ctDNA Testing in Metastatic Breast Cancer Patients with no Evidence of Disease: Potential Clinical Utility from Real-world Data

Caterina Gianni, United States

PP01.39

Development of an Expert Consensus on the Clinical Utility of Circulating Tumor Cells in Solid Tumors

Eleonora Nicolò, United States

PP01.40

Circulating Tumor DNA Mutations as Markers for Brain Metastases at Diagnosis and During Treatment

Rodrigo Paredes de la Fuente, United States

PP01.41

Multimomics Analysis in Longitudinal Series of Plasma Samples of p.G12NSCLC Patients Under Target Treatment

Francesco Pepe, Italy

PP01.42

MicroOrganoSphere (MOS): A Novel Technology for Circulating Tumor Cell (CTC)- derived Organoid Formation

Elisabetta Molteni, United States

PP01.43

Liquid Biopsy Detection of Gene Copy Number (CN) Losses Including Existing and Emerging Clinical Targets

Christian Rolfo, United States

PP01.44

Comprehensive Circulating Cytokine/Chemokine Profiles for Monitoring and Predicting Clinical Outcomes in Melanoma Neoadjuvant Immunotherapy

Dhruvajyoti Roy, United States

PP01.45

Circulating Tumor DNA (ctDNA) Analysis for Precision Oncology: A Tertiary Oncology Centre Perspective in India

Omeshree Shetty, India

PP01.46

Pan-Cancer Analysis of Pre-Treatment Circulating Tumor DNA (ctDNA) in Patients from the Princess Margaret Liquid Biopsy Program

Scott Strum, Canada

PP01.47

Ultra-sensitive Molecular Residual Disease Detection Through Whole Genome Sequencing with Single-read Error Correction

John Kern, United States

PP01.48

Evaluation of Full Spectrum Cell-free RNA in Peripheral Blood as Potential Biomarker for Acute myeloid leukemia disease profiling

Deepshi Thakral, India

PP01.51

ESR1 ctDNA Testing in HR+/HER2 Metastatic Breast Cancer: A Real-world Perspective From a Referral Laboratory

Konstantinos Venetis, Italy

PP01.52

ctDNA-Based Detection of Homologous Recombination Deficiency in mCRPC Patients

Georgios Vlachos, Austria

Clinical Trials Including Liquid Biopsies

PP01.53

Pioneering South Florida's First Minority-Focused Breast Cancer Biorepository: Leveraging Liquid Biopsy, NGS, and ctDNA for Advancements in Precision Medicine

Andres Alvarez Pinzon, United States

PP01.54

Exploratory Analysis of ctDNA and Imaging Response in Phase I/II CHORUS Study of Canakinumab With Chemoradiation and Durvalumab for NSCLC

Karmelina Charalambous, United States

PP01.55

The SURVIVE Study - Liquid Biopsy Guided Surveillance in Intermediate- to high-risk Early Breast Cancer

Christodoulos Pipinikas, United States

PP01.56

A Randomized Trial of Immune Checkpoint Inhibitor Plasma Proteomic Biomarker and Chemotherapy Risk Model in Advanced Non-Small Cell Lung Cancer

Surbhi Singhal, United States

Composite Biomarkers Using Liquid Biopsy

PP01.58

Fluorescent dCFPyL (GUL-Cy5) for Detecting Circulating Tumor and Immune Cells Containing Cancer Extracellular Vesicles in Early Metastatic Prostate Cancer Prognostication

Omar Alawamry, Canada

PP01.59

Identification of Genomic Features Associated with ctDNA Shedding in Non Small Cell Lung Cancer

Anna Di Lello, United States

PP01.60

GFAP, UCH-L1, Tau and NfL as Potential Biomarkers for Glioblastoma Diagnosis and Monitoring: a Retrospective Study

Jonathan Decarpentrie, Belgium

PP01.61

Liquid Biopsy-Derived Proteomic Signature for Tailoring Non-Small Cell Lung Cancer Immunotherapy Strategies

Michal Harel, Israel

PP01.62

Non-invasive Immunogram to Characterize and Monitor Immune Status in Non-Small Cell Lung Cancer Patients Treated with Immunotherapy.

Andrea Moreno-Manuel, España

PP01.63

Algorithmic Genomic Alteration Filtering and Circulating Tumor DNA (ctDNA) Quantification in Serial Liquid Biopsy (LBx) From Patients With ProstateCancer

Umberto Malapelle, Italy

PP01.64

Computational Variant Origin Prediction (VOP) to Distinguish Germline, Tumor Somatic, and Clonal Hematopoiesis (CH) Variants in Liquid Biopsy (LBx)

Bruna Pellini, United States

Comprehensive Liquid Biopsy Analysis in Different Matrices

PP01.67

Assessing Mutational Status in NSCLC through Exosomal Liquid Biopsies

Susana Torres-Martínez, Spain

PP01.68

DEGs Analysis of Circulating Tumor Cells (CTCs) and Tissue Tumor Cells in Costa Rican HER2 Positive Metastatic Breast Cancer Patients.

Ricardo Chinchilla-Monge, Costa Rica

Liquid Biopsy in Early Cancer Detection

PP01.73

Circulating Tumour Cell Isolation and Enrichment for Investigation of Prostate Cancer Metastasis

Sophia Abusamra, United States

PP01.74

Analytical Results of a Tumor-informed Digital Droplet PCR Approach for Minimal Residual Disease

Anna Klemantovich, Canada

PP01.75

Identification of Tumor-marker Gangliosides in Serum for Early-Stage Cancer Diagnosis

Rachel Culp-Hill, United States

PP01.76

Characterizing the Cell-free Transcriptome in a Humanized DLBCL Patient-Derived Tumor Xenograft Model for RNA-Based Liquid Biopsy in a Preclinical Setting

Philippe Decruyenaere, Belgium

PP01.77

Minimally Invasive Image Guided Percutaneous Lung Nodule Resection for Definitive Diagnosis and Treatment of Lung Cancer

Richard Fischel, CA

PP01.78

Advanced CNA-Informed Fragmentomics Enhances Cross-Cohort Tumor Detection

Piera Grisolia, United States

PP01.79

Enhancing Sensitivity of ctDNA Copy Number Detection by Increasing Plasma Sample Volume

Nafiseh Jafari, United States

PP01.80

Potential of Circulating MicroRNAs as Biomarkers in Perioperative Management of Lung Cancer

Joji Samejima, Japan

PP01.81

Smart BioSurface® Technology for Prostate Cancer Detection and Risk Stratification through CTC Enumeration and Biomarker Expression Profiling

Francesca Senic-Matuglia, Italy

PP01.82

Detection of Circulating Tumor DNA After Stereotactic Ablative Radiotherapy in Patients with Unbiopsied Lung Tumors (SABR-DETECT)

Saurav Verma, Canada

Liquid Biopsy in Non-Oncological Conditions

PP01.83

Cell-Free RNA Liquid Biopsies Uncover Transcriptional Networks Underlying Sepsis

Nicholas Semenkovich, United States

PP01.84

Optimizing High-Quality RNA Retrieval from Dried Blood Microsamples for RNA Sequencing

Elena Ramos Varas, Belgium

Miscellaneous

PP01.86

Automated Analysis Pipeline for HER2 Expression Profiling in CTCs: Computational Potential for Advancing Personalized Therapy for Metastatic Breast Cancer

Sarah Henretta, United States

PP01.87

Trends in Physician Perception and Use of Liquid Biopsy in NSCLC within the US

Hope Bender, United States

PP01.88

Assessing the Performance of cfDNA Extraction from Plasma

Zandra Deans, United Kingdom

PP01.89

Economic and Clinical Impact of Integrating the PROphetNSCLC Plasma Proteomic Test in mNSCLC Treatment

Yehonatan Elon, Israel

PP01.90

Unlocking the Full Potential of Liquid Biopsy: A Polymer Method for the Reagent-free Recovery and Storage of DNA from Biofluids

Matthew Owens, United Kingdom

NOW ENROLLING

SOHO-02 A Phase 3 open-label, randomized, multicenter trial to evaluate efficacy and safety of oral BAY 2927088 compared with standard of care as a first-line therapy in patients with locally advanced or metastatic **NSCLC with HER2-activating mutations**

For complete information please visit:
[http://www.clinicaltrials.gov \(NCT06452277\)](http://www.clinicaltrials.gov (NCT06452277))



SOHO 02
CLINICAL STUDY

© 2024 Bayer.
Bayer and the Bayer Cross are
registered trademarks of Bayer.
MA-PFM-ONC-US-0431-1 09/2024